Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression

Despite extensive efforts to find new treatments, chemotherapy is still one of the first and foremost choices for cancer treatment. The main problems of using these drugs are the resistance of cancer cells and reducing their sensitivity to chemotherapy as well as the side effects of their systemic a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Life sciences (1973) 2021-06, Vol.275, p.119369-119369, Article 119369
Hauptverfasser:	Joshi, Navneet, Hajizadeh, Farnaz, Ansari Dezfouli, Ehsan, Zekiy, Angelina Olegovna, Nabi Afjadi, Mohsen, Mousavi, Seyedeh Mahboubeh, Hojjat-Farsangi, Mohammad, Karpisheh, Vahid, Mahmoodpoor, Ata, Hassannia, Hadi, Dolati, Sanam, Mohammadi, Hamed, Yousefi, Mehdi, Jadidi-Niaragh, Farhad
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibiotics, Antineoplastic - therapeutic use Apoptosis Cancer Cancer therapies Cell death Cell Line, Tumor Chemotherapy Chitosan Doxorubicin Doxorubicin - therapeutic use Drug resistance Drug Resistance, Neoplasm - genetics Female Folic acid Gene Silencing Humans Immune response Immunosuppressive agents Lactic acid Medicin och hälsovetenskap Mice Mice, Inbred BALB C Nanoparticle Nanoparticles Neoplasm Transplantation Neoplasms - drug therapy Neoplasms - pathology Neoplasms - therapy RNA, Small Interfering - administration & dosage RNA, Small Interfering - therapeutic use Sensitivity enhancement Side effects siRNA STAT3 Stat3 protein STAT3 Transcription Factor - metabolism Transcriptome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!